Stephens Investment Management Group LLC Purchases 19,434 Shares of DexCom, Inc. (NASDAQ:DXCM)

Stephens Investment Management Group LLC raised its position in DexCom, Inc. (NASDAQ:DXCM) by 2.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 703,919 shares of the medical device company’s stock after purchasing an additional 19,434 shares during the period. Stephens Investment Management Group LLC owned 0.18% of DexCom worth $54,744,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter valued at $25,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the period. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the 4th quarter valued at about $38,000. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the 3rd quarter valued at about $57,000. Finally, Covestor Ltd grew its stake in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 over the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $88.08 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a market cap of $34.40 billion, a PE ratio of 52.74, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The stock’s fifty day simple moving average is $81.76 and its two-hundred day simple moving average is $75.62. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Analyst Ratings Changes

Several brokerages have issued reports on DXCM. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Canaccord Genuity Group upped their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Wells Fargo & Company raised their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $98.41.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.